A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer.

Trial Profile

A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs SM 88 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 12 Sep 2017 Interim results (n=8) presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 According to a Tyme Technologies media release, the phase II part of the trial is expected to be complete in the first half of 2018.
    • 11 Sep 2017 Interim results published in a Tyme Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top